

UBS Convert Global Bond Fund EUR I-X-dist

Fund Fact Sheet

UBS Bond Funds > UBS Convertible Funds

Fund description

- The actively managed fund invests worldwide in convertible bonds.
- Convertible bonds combine the upside potential of equities and the defensive characteristics of bonds.
- The investment objective is to take full advantage of the beneficial risk-return characteristics of the global convertible bond markets.

Please see additional information on the following page. 2.


Name of fund	UBS (Lux) Bond SICAV - Convert Global (EUR)
Share class	UBS (Lux) Bond SICAV - Convert Global (EUR) I-X-dist
ISIN	LU0396332644
Securities no.	4 731 791
Bloomberg	UBCGIXD LX
Currency of fund / share class	EUR/EUR
Launch date	31.10.2011
Issue/redemption	daily
Swing pricing	yes
Accounting year end	31 May
Benchmark	Refinitiv Global Convertible Index - Global Vanilla (hedged EUR)
Ø effective duration	1.69
Ø Yield-to-worst ¹	-1.68%
Ø premium to investment value	20.81%
Distribution	August
Last distribution 06.08.2024	EUR 2.79
Management fee p.a.	0.00%
Ongoing costs p.a. ²	0.02%
Name of the Management Company	UBS Fund Management (Luxembourg) S.A., Luxembourg
Fund domicile	Luxembourg
SFDR Classification	Art.8

¹ This does not constitute a guarantee by UBS Asset Management.
² As at 17.07.2024, without transaction costs

Fund Statistics

Net asset value (EUR, 30.08.2024)	181.70
Last 12 months (EUR) – high	186.98
– low	165.14
Total fund assets (EUR m) (30.08.2024)	3 954.35
Share class assets (EUR m)	731.98

Performance (basis EUR, net of fees)¹



Past performance is not a reliable indicator of future results.

in %	2021	2022	2023	2024 YTD ²	Aug. 2024	LTD ³	Ø p.a. 3 years	Ø p.a. 5 years
Fund (EUR)	3.43	-16.94	11.31	4.06	0.15	125.76	-2.42	4.98
Benchmark ⁴	-0.44	-19.10	10.86	4.36	1.37	117.80	-3.74	5.27

The performance shown does not take account of any commissions, entry or exit charges.

¹ These figures refer to the past. **If the currency of a financial product, financial service or its costs is different from your reference currency, the return and/or costs can increase or decrease as a result of currency fluctuations.** Source for all data and chart (if not indicated otherwise): UBS Asset Management.

² YTD: year-to-date (since beginning of the year)

³ LTD: launch-to-date

⁴ Reference Index in currency of share class (without costs)

in %	03.2024	04.2024	05.2024	06.2024	07.2024	08.2024
Fund (EUR)	2.71	-1.07	1.67	0.45	0.62	0.15
Benchmark	1.98	-2.57	1.64	0.72	0.97	1.37

Key Figures

	2 years	3 years	5 years
Beta	0.88	0.88	0.89
Correlation	0.98	0.98	0.98
Volatility ¹			
– Fund	8.16%	9.07%	11.36%
– Benchmark	9.09%	10.12%	12.52%
Tracking error (ex post)	2.04%	2.12%	2.56%
Information ratio	0.37%	0.62%	-0.12%
Sharpe ratio	0.39	-0.48	0.35
Risk free rate	3.12%	1.92%	0.96%
R2	0.96	0.96	0.96

¹ Annualised standard deviation

For more information

UBS Fund Infoline: 0800 899 899
Internet: www.ubs.com/funds
Contact your client advisor

Portfolio management representatives

Ulrich Sperl
Alain Eckmann

UBS Convert Global Bond Fund EUR I-X-dist

Credit quality (%)

	Fund
AAA	0.0
AA	16.7
A	27.8
BBB	35.0
BB	8.0
B	4.0
CCC	0.6
CC	0.3
C	1.5
Others	6.2

Structure of maturities (%)

	Fund
Until 1 year	10.2
1–3 years	24.5
3–5 years	35.8
More than 5 years	29.5

Benefits

Investors participate in some of the price gains when equity markets are rising, and benefit from the defensive characteristics of a bond investment in falling markets. The portfolio's return potential is considerably increased using carefully selected convertible bonds, without incurring significant additional risk.

Additional information

- Foreign currencies are largely hedged versus the reference currency.
- The portfolio manager is not tied to the benchmark in terms of investment selection or weight.

10 largest positions (%)

	Fund
Palo Alto Networks 0.375% 2025	1.54
Ping An Insurance 0.875% 2029	1.52
Rivian Automotive 3.625% 2030	1.50
Alnylam Pharmaceuticals 1% 2027	1.44
Western Digital 3% 2028	1.30
Danone(BNP)0% 2024	1.28
ON Semiconductor 0% 2027	1.23
Zscaler 0.125% 2025	1.06
Halozyme Therapeutics 0.25% 2027	1.05
Uber Technologies 0.875% 2028	1.04

Market exposure (%)

	Fund	Deviation from index
United States	48.68	-20.7
Eurozone	25.87	+8.9
Japan	9.67	+4.8
Asia ex Japan	7.43	+0.3
Cash	5.87	+5.9
Others	2.48	+0.9

Risks

The fund invests mainly in convertible bonds. Changes in equity prices, interest rates, credit quality and other factors can subject the fund to high fluctuations in value, which are for the most part less pronounced than with equities but significantly higher than with traditional corporate bonds. The fund may use derivatives which can reduce investment risk or give rise to additional risks (inter alia the counterparty risk). The fund can invest in less liquid assets that may be difficult to sell in the case of distressed markets. The value of a unit may fall below the purchase price. This requires an elevated risk tolerance and capacity. Every fund reveals specific risks, a description of these risks can be found in the prospectus. This Fund may not be appropriate for investors who plan to withdraw their money before the recommended holding period disclosed in the PRIIPs KID, if available for this share class.

Please note that additional fees (e.g. entry or exit fees) may be charged. Please refer to your financial adviser for more details. Investors should read the Key Information Document, Prospectus and any applicable local offering document prior to investing and to get complete information of the risks. Investors are acquiring units or shares in a fund, and not in a given underlying asset such as building or shares of a company. For a definition of financial terms refer to the glossary available at www.ubs.com/am-glossary.

For marketing and information purposes by UBS. For professional clients / qualified investors only. UBS funds under Luxembourg law. Arrangements for marketing fund units mentioned in this document may be terminated at the initiative of the management company of the fund(s). Before investing in a product please read the latest prospectus and key information document carefully and thoroughly. Any decision to invest should take into account all the characteristics or objectives of the fund as described in its prospectus, or similar legal documentation. Investors are acquiring units or shares in a fund, and not in a given underlying asset such as building or shares of a company. The information and opinions contained in this document have been compiled or arrived at based upon information obtained from sources believed to be reliable and in good faith, but is not guaranteed as being accurate, nor is it a complete statement or summary of the securities, markets or developments referred to in the document. Members of the UBS Group may have a position in and may make a purchase and / or sale of any of the securities or other financial instruments mentioned in this document. Units of UBS funds mentioned herein may not be eligible for sale in all jurisdictions or to certain categories of investors and may not be offered, sold or delivered in the United States. The information mentioned herein is not intended to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. Past performance is not a reliable indicator of future results. The calculated performance takes all costs on the fund level into consideration (ongoing costs). The entry and exit costs, which would have a negative impact on the performance, are not taken into consideration. If whole or part of the total costs to be paid is different from your reference currency, the costs may increase or decrease as a result of currency and exchange rate fluctuations. Commissions and costs have a negative impact on the investment and on the expected returns. If the currency of a financial product or financial service is different from your reference currency, the return can increase or decrease as a result of currency and exchange rate fluctuations. This information pays no regard to the specific or future investment objectives, financial or tax situation or particular needs of any specific recipient. Future performance is subject to taxation which depends on the personal situation of each investor and which may change in the future. The details and opinions contained in this document are provided by UBS without any guarantee or warranty and are for the recipient's personal use and information purposes only. This document may not be reproduced, redistributed or republished for any purpose without the written permission of UBS Asset Management Switzerland AG or a local affiliated company. Source for all data and charts (if not indicated otherwise): UBS Asset Management. The product described herein aligns to Article 8 Regulation (EU) 2019/2088 on sustainability-related disclosures in the financial services sector. Information on sustainability-related aspects pursuant to that regulation can be found on www.ubs.com/funds. The benchmark is the intellectual property of the respective index provider. The fund or the share class is neither sponsored nor endorsed by the index provider. The fund prospectus or supplemental prospectus contains the full disclaimer. This document contains statements that constitute "forward-looking statements", including, but not limited to, statements relating to our future business development. While these forward-looking statements represent our judgments and future expectations concerning the development of our business, a number of risks, uncertainties and other important factors could cause actual developments and results to differ materially from our expectations. **Switzerland:** Representative in Switzerland for UBS funds established under foreign law: UBS Fund Management (Switzerland) AG, P.O. Box, CH-4002 Basel. Paying agent: UBS Switzerland AG, Bahnhofstrasse 45, CH-8001 Zurich. Prospectuses, key information document, the articles of association or the management regulations as well as annual and semi-annual reports of UBS funds are available in a language required by the local applicable law free of charge from UBS Asset Management Switzerland AG, c/o UBS AG, Bahnhofstrasse 45, 8001 Zürich, Switzerland or from UBS Fund Management (Switzerland) AG, P.O. Box, CH-4002 Basel. A summary of investor rights in English can be found online at www.ubs.com/funds. More explanations of financial terms can be found at www.ubs.com/am-glossary.

© UBS 2024. The key symbol and UBS are among the registered and unregistered trademarks of UBS. All rights reserved.